Rapid LVO

Rapid LVO 1.0 is designed to expedite the identification of potential Large Vessel Occlusions in CTA head scans, serving as a radiological computer-aided triage and notification tool. It employs a software algorithm to analyze images and alert clinicians to suspected LVOs, thereby aiming to improve workflow prioritization for patients with acute ischemic stroke without replacing standard diagnostic procedures.

Rapid LVO 1.0 is a radiological computer-aided triage and notification software specifically designed to analyze CTA head images for suspected Large Vessel Occlusions (LVOs). Its purpose is to assist hospital networks and trained radiologists by flagging potential LVO cases to streamline workflow triage. The system, a module within the broader Rapid Platform, utilizes a software algorithm to process DICOM-compliant CTA images, operating in parallel with standard image interpretation. It then issues notifications, including compressed preview images (for informational purposes only), to users via server, desktop application, email, or mobile, highlighting cases that may require urgent attention for acute ischemic stroke. The software does not modify original medical images and is not a standalone diagnostic tool; its outputs are intended to support clinical judgment and image prioritization. Performance validation demonstrated high accuracy with a sensitivity of 0.970 and specificity of 0.956 for LVO detection, and an ROC AUC of 0.99. A key operational feature is its rapid notification capability, achieving an average time-to-notification of 2.86 minutes from image acquisition to alert delivery. Clinicians are always responsible for reviewing full, non-compressed images on a diagnostic viewer before making patient care decisions.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the Rapid LVO algorithm differentiate between true LVOs and mimics, such as severe stenosis or artifacts, in CTA imaging?; What impact does the 2.86-minute notification time have on 'door-to-treatment' times in real-world clinical settings for LVO patients?; Given the performance metrics (Se 0.970, Sp 0.956), what is the anticipated rate of false positives and false negatives in a typical stroke center population, and what are the clinical implications?; How does the system handle variations in CTA image quality, contrast timing, or scanner protocols, and does this impact its detection accuracy?; Beyond simple notification, are there plans to integrate advanced quantitative LVO characteristics (e.g., clot burden, location detail) into the preview information provided by Rapid LVO?